Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Receivables (2017 - 2025)

Ligand Pharmaceuticals' Non-Current Receivables history spans 4 years, with the latest figure at $196.9 million for Q4 2025.

  • For Q4 2025, Non-Current Receivables rose 6.41% year-over-year to $196.9 million; the TTM value through Dec 2025 reached $196.9 million, up 6.41%, while the annual FY2025 figure was $196.9 million, 6.41% up from the prior year.
  • Non-Current Receivables for Q4 2025 was $196.9 million at Ligand Pharmaceuticals, down from $206.3 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $206.3 million in Q3 2025 and bottomed at $2.5 million in Q2 2024.
  • The 3-year median for Non-Current Receivables is $188.3 million (2025), against an average of $144.4 million.
  • The largest YoY upside for Non-Current Receivables was 7642.24% in 2025 against a maximum downside of 3.55% in 2025.
  • A 3-year view of Non-Current Receivables shows it stood at $62.3 million in 2023, then skyrocketed by 197.03% to $185.0 million in 2024, then rose by 6.41% to $196.9 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Non-Current Receivables are $196.9 million (Q4 2025), $206.3 million (Q3 2025), and $193.6 million (Q2 2025).